Cost-effectiveness analysis of outpatient bispecific antibody treatment for multiple myeloma.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the cost-utility of escalating doses of bispecific antibodies in patients with relapsed or refractory multiple myeloma. It compares the outcomes of patients treated in an outpatient setting versus those in a conventional hospital unit, focusing on quality of life and clinical data collected at multiple time points. The study utilizes validated questionnaires to assess patient utility and quality of life, while also gathering economic data related to hospital stays. The aim is to determine the feasibility and effectiveness of outpatient treatment for this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Relapsed and/or refractory multiple myeloma
* Treated with teclistamab, elranatamab ou talquetamab
* More than 18 years old
* Having received the information from the study and not having objected to participate
* Day hospital care in case of clinical feasibility (good general condition, no rapid progression or major tumor burden, no current infection) and logistics (accommodated less than 30 minutes from the IUCT Oncopole for 48 hours after each dose escalation) or in conventional hospitalization at the IUCT Oncopole

Exclusion Criteria:

* Illiterate subjects or those with a language barrier

Where it's running

• CHU de Toulouse
  Toulouse, France Recruiting

Study contacts

• Study coordinator: Aurore PERROT, Md, PhD
• Email: perrot.aurore@iuct-oncopole.fr
• Phone: 0531155050

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• In Vivo BCMA-CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma

  This study tests VV169, a one-time in vivo CAR-T treatment, in adults with multiple myeloma that has come back or not responded to standard therapy.

  Recruiting Phase 1 Vyriad, Inc. · Rochester, Minnesota · NCT07802717

• Inobrodib with Pomalidomide and Dexamethasone vs Standard Therapy for Relapsed or Refractory Myeloma

  This study tests whether inobrodib with pomalidomide and dexamethasone helps people with relapsed or refractory multiple myeloma more than the standard available therapy.

  Recruiting Phase 3 CellCentric Ltd. · Miami, Florida · NCT07772024

• CAR-T therapy for relapsed or refractory multiple myeloma

  This study tests a CAR-T therapy in people with multiple myeloma whose disease has come back or not responded to treatment.

  Recruiting at 2 sites Phase 2 National Institute of Blood and Marrow Transplant (NIBMT), Pakistan · Rawalpindi, Punjab Province and 1 other locations · NCT07689058

• Elranatamab given as outpatient in relapsed or refractory multiple myeloma

  This study tests a bispecific antibody called elranatamab, given in an outpatient setting to adults with relapsed or refractory multiple myeloma who have had prior therapies.

  Recruiting at 6 sites Phase 2 SCRI Development Innovations, LLC · Denver, Colorado and 5 other locations · NCT07637578

• Liposomal Curcumin in Multiple Myeloma: safety and dose finding

  This trial tests a novel liposomal curcumin infusion to see if it is safe and what highest tolerable dose is for adults whose multiple myeloma has returned or not responded to treatment.

  Recruiting Phase 1 University Health Network, Toronto · Toronto, Ontario · NCT07456605

• Off-the-shelf BCMA CAR‑T for relapsed or refractory multiple myeloma

  This trial will try a universal (allogeneic) BCMA-directed CAR‑T cell treatment for people with relapsed or refractory multiple myeloma to see if it is safe and can reduce disease.

  Recruiting Bioray Laboratories · Shanghai · NCT07248176

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.